Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.

Abstract

Recurrent transitional cell carcinoma was treated with prophylactic intravesical thio-tepa in 22 cases. Group 1 patients were treated with 30 mg. twice daily for the first 3 days postoperatively. Group 2 patients were given additional treatment at increasing intervals indefinitely. Before therapy control patients averaged 1 recurrence every 9.5 months. Group 1 patients averaged 1 recurrence per 33 mpnths. Group 2 patients averaged 1 recurrence per 41 months. Leukopenia occurred in only 2 patients. Thio-tepa can be given safely in the immediate postoperative period and is effective in decreasing the recurrence rate of superficial bladder tumors.

• Authors: G J Gavrell, R W Lewis, W L Meehan, G A Leblanc
• Journal: The Journal of urology (J Urol) Vol. 120 Issue 4 Pg. 410-1 (Oct 1978) ISSN: 0022-5347 [Print] United States
• PMID: 100615 (Publication Type: Journal Article)

Chemical References

• Thiotepa

Topics

• Adolescent
• Adult
• Aged
• Animals
• Carcinoma, Transitional Cell (prevention & control)
• Child
• Child, Preschool
• Dogs
• Follow-Up Studies
• Humans
• Infant
• Leukopenia (chemically induced)
• Middle Aged
• Neoplasm Recurrence, Local (prevention & control)
• Postoperative Period
• Thiotepa (adverse effects, therapeutic use)
• Urinary Bladder Neoplasms (prevention & control)